Mayne Pharma Group Limited announced that Carolyn Myers has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately. Dr. Myers was nominated by Mayne Pharma's 9.6% shareholder, Mithra Pharmaceuticals SA, as required under the license and supply agreement to commercialise NEXTSTELLISÒ (E4/DRSP) oral contraceptive in the United States. She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogen- repelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies.